Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1809 results
August 2018
-
Key Release
Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer
Basel, August 14, 2018 - Novartis announced today the appointment of Dr Klaus Moosmayer as Chief Ethics, Risk and Compliance Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and… -
Story Discovery
New drug manufacturing tools change pharma chemistry
The modernization and miniaturization of pharmaceutical production could expand the range of ingredients medicinal chemists use to make new drugs.
-
Story Discovery
Embracing big data to understand complex diseases
Researchers discover that networks of proteins circulating in the blood influence the development and progression of chronic diseases.
-
Story Discovery
Discovery gives cystic fibrosis researchers new direction
Novartis-Harvard team identifies a new type of cell that is key to the disease.
July 2018
-
Story Access to Healthcare
Meet Manuel Cobos, transplant surgeon and researcher
Follow Dr. Cobos as he works to provide a patient with a new liver and performs surgery using a tiny video camera.
-
Media Release
Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention
Patients on Aimovig (erenumab) in clinical trials reported consistent and sustained migraine prevention, with many experiencing a 50% or more reduction in monthly migraine days; safety and… -
Story Discovery
Quest for a new measure of mental health
Novartis researchers are searching for more effective ways to discover drugs for neurological and psychiatric diseases.
-
Media Release
Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)
Biosimilar Hyrimoz® (adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and dermatology Early therapeutic intervention is… -
Media Release
Novartis combination Tafinlar® + Mekinist® receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanoma
Phase III trial showed a 53% reduction in risk of recurrence or death with the combination of a BRAF and MEK inhibitor as adjuvant therapy versus placebo[1] Relapse-free survival benefit with… -
Media Release
Novartis renews drug donation of Egaten® (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke
Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million… -
Media Release
Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitis
Novartis enters an exclusive license agreement with Galapagos and MorphoSys for an investigational biologic compound, MOR106, a novel antibody directed against IL-17C IL-17C is believed to… -
Media Release
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
Kisqali is now the only CDK4/6 inhibitor indicated in combination with an aromatase inhibitor as first-line treatment for pre-, peri- or postmenopausal women with HR+/HER2- advanced breast cancer…